dabigatran etexilate mesylate

dabigatran etexilate mesylate

(də-bĭg′ə-trăn′ ē-tĕk′sə-lāt′)
n.
A thrombin inhibitor used to decrease the risk of stroke or embolism formation in people with certain forms of atrial fibrillation and to treat or reduce the recurrence risk of deep vein thrombosis and pulmonary embolism.
Mentioned in ?
References in periodicals archive ?
Dabigatran etexilate mesylate (Pradaxa; Boehringer Ingelheim Pharmaceuticals, Inc.
The Food and Drug Administration has already approved three such medications -- apixaban (Eliquis), dabigatran etexilate mesylate (Pradaxa) and rivaroxaban (Xarelto) -- and others are being studied.
The FDA has advised pharmacists to dispense the anticoagulant medication dabigatran etexilate mesylate (Pradaxa) only in the original manufacturer bottles or blister packages because of concerns about product breakdown, according to a MedWatch statement.